Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 104-110 |
| Number of pages | 7 |
| Journal | Brachytherapy |
| Volume | 19 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2020 |
Keywords
- Brachytherapy
- Esophageal cancer
- Interventional radiotherapy
- Palliative
- argon plasma coagulation
- brachytherapy
- cancer palliative therapy
- cancer radiotherapy
- cancer survival
- dysphagia
- esophagus cancer
- esophagus fistula
- esophagus stenosis
- external beam radiotherapy
- follow up
- human
- intraoperative radiotherapy
- outcome assessment
- patient safety
- photodynamic therapy
- priority journal
- Review
- systematic review
- adverse device effect
- adverse event
- complication
- esophagus tumor
- palliative therapy
- procedures
- radiation injury
- randomized controlled trial (topic)
- stent
- survival rate
- Deglutition Disorders
- Esophageal Fistula
- Esophageal Neoplasms
- Esophageal Stenosis
- Humans
- Palliative Care
- Radiation Injuries
- Randomized Controlled Trials as Topic
- Stents
- Survival Rate
Fingerprint
Dive into the research topics of 'The role of palliative interventional radiotherapy (brachytherapy) in esophageal cancer: An AIRO (Italian Association of Radiotherapy and Clinical Oncology) systematic review focused on dysphagia-free survival'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
The role of palliative interventional radiotherapy (brachytherapy) in esophageal cancer: An AIRO (Italian Association of Radiotherapy and Clinical Oncology) systematic review focused on dysphagia-free survival. / Lancellotta, V.; Cellini, F.; Fionda, B.; De Sanctis, V.; Vidali, C.; Fusco, V.; Barbera, F.; Gambacorta, M.A.; Corvò, R.; Magrini, S.M.; Tagliaferri, L.
In: Brachytherapy, Vol. 19, No. 1, 2020, p. 104-110.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - The role of palliative interventional radiotherapy (brachytherapy) in esophageal cancer: An AIRO (Italian Association of Radiotherapy and Clinical Oncology) systematic review focused on dysphagia-free survival
AU - Lancellotta, V.
AU - Cellini, F.
AU - Fionda, B.
AU - De Sanctis, V.
AU - Vidali, C.
AU - Fusco, V.
AU - Barbera, F.
AU - Gambacorta, M.A.
AU - Corvò, R.
AU - Magrini, S.M.
AU - Tagliaferri, L.
N1 - Cited By :4 Export Date: 4 February 2021 CODEN: BRACC Correspondence Address: Fionda, B.; Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Italy; email: bruno.fionda@yahoo.it References: Pisani, P., Parkin, D.M., Bray, F., Estimates of the worldwide mortality from 25 cancers in 1990 (1999) Int J Cancer, 83, pp. 18-29; Allemani, C., DaTomohiro, M., Di Carlo, V., Best palliation in esophageal: surgery, stenting, radiation, or what? (2001) Dis Esophagus, 14, pp. 120-123; Cunningham, D., Allum, W.H., Stenning, S.P., Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer (2006) N Engl J Med, 355, pp. 11-20; Noordman, B.J., Verdam, M.G.E., Lagarde, S.M., Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer: Results from the randomized CROSS trial (2018) J Clin Oncol, 36, pp. 268-275; Cellini, F., Morganti, A.G., Di Matteo, F.M., Clinical management of gastroesophageal junction tumors: Past and recent evidences for the role of radiotherapy in the multidisciplinary approach (2014) Radiat Oncol, 9, p. 45; Cellini, F., Valentini, V., Targeted therapies in combination with radiotherapy in oesophageal and gastroesophageal carcinoma (2014) Curr Med Chem, 21, pp. 990-1004; Cellini, F., Ramella, S., Ciresa, M., Role of induction therapy in esophageal cancer (2005) Rays, 30, pp. 329-333; Weigel, T.L., Frumiento, C., Gaumintz, E., Endoluminal palliation for dysphagia secondary to esophageal carcinoma (2002) Surg Clin North Am, 82, pp. 747-761; Siersema, P.D., Dees, J., van Blankenstein, M., Palliation of malignant dysphagia from oesophageal cancer. Rotterdam oesophageal tumor study group (1998) Scand J Gastroenterol Suppl, 225, pp. 75-84; Siersema, P.D., Hop, W.C., van Blankenstein, M., A comparison of 3 types of covered metal stents for the palliation of patients with dysphagia caused by esophagogastric carcinoma; a prospective, randomized study (2001) Gastrointest Endosc, 54, pp. 145-153; Burstow, M., Kelly, T., Panchani, S., Outcome of palliative esophageal stenting for malignant dysphagia: A retrospective analysis (2009) Dis Esophagus, 22, pp. 519-525; Madhusudhan, C., Saluja, S.S., Pal, S., Palliative stenting for relief of dysphagia in patients with inoperable esophageal cancer: Impact on quality of life (2009) Dis Esophagus, 22, pp. 331-336; Fuccio, L., Mandolesi, D., Farioli, A., Brachytherapy for the palliation of dysphagia owing to esophageal cancer: A systematic review and meta-analysis of prospective studies (2017) Radiother Oncol, 122, pp. 332-339; Brown, S.G., Palliation of malignant dysphagia: Surgery, radiotherapy, laser, intubation alone or in combination? (1991) Gut, 32, pp. 841-844; Hayter, C.R., Huff–Winters, C., Paszat, L., A prospective trial of short-course radiotherapy plus chemotherapy for palliation of dysphagia from advanced esophageal cancer (2000) Radiother Oncol, 56, pp. 329-333; Homs, M.Y., Steyerberg, E.W., Eijkenboom, W.M., Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: A multicentre randomized trial (2004) Lancet, 364, pp. 1497-1504; Bergquist, H., Wenger, U., Johnsson, E., Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial (2005) Dis Esophagus, 18, pp. 131-139; Spencer, G.M., Thorpe, S.M., Blackman, G.M., Laser augmented by brachytherapy versus laser alone in the palliation of adenocarcinoma of the oesophagus and cardia: A randomised study (2002) Gut, 50, pp. 224-227; Sander, R., Hagenmueller, F., Sander, C., Laser versus laser plus afterloading with iridium-192 in the palliative treatment of malignant stenosis of the esophagus: A prospective, randomized, and controlled study (1991) Gastrointest Endosc, 37, pp. 433-440; Sur, R., Donde, B., Falkson, C., Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer (2004) Brachytherapy, 3, pp. 191-195; Rosenblatt, E., Jones, G., Sur, R.K., Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: A prospective multi-centre randomized trial of the international atomic energy agency (2010) Radiother Oncol, 97, pp. 488-494; Rupinski, M., Zagorowicz, E., Regula, J., Randomized comparison of three palliative regimens including brachytherapy, photodynamic therapy, and APC in patients with malignant dysphagia (CONSORT 1a) (revised II) (2011) Am J Gastroenterol, 106, pp. 1612-1620; Steyerberg, E.W., Homs, M.Y.V., Stokvis, A., Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: A prognostic model to guide treatment selection (2005) Gastrointest Endosc, 62, pp. 333-340; Ferrandina, G., Lucidi, A., Paglia, A., Role of comorbidities in locally advanced cervical cancer patients administered preoperative chemoradiation: Impact on outcome and treatment-related complications (2012) Eur J Surg Oncol, 38, pp. 238-244; Lancellotta, V., Kovács, G., Tagliaferri, L., Age is not a limiting factor in interventional radiotherapy (brachytherapy) for patients with localized cancer (2018) Biomed Res Int, 2018, p. 2178469; Homs, M.Y., Eijkenboom, W., Coen, V., High dose rate brachytherapy for the palliation of malignant dysphagia (2003) Radiother Oncol, 66, pp. 327-332; Opstelten, J.L., de Wijkerslooth, R.H., Leenders, M., Variation in palliative care of esophageal cancer in clinical practice: Factors associated with treatment decisions (2017) Dis Esophagus, 30, pp. 1-7; Dai, Y., Li, C., Xie, Y., Interventions for dysphagia in oesophageal cancer (2014) Cochrane Database Syst Rev, 10, p. CD005048; Spaander, M.C.W., Baron, T.H., Siersema, P.D., Esophageal stenting for benign and malignant disease: European Society of gastrointestinal endoscopy (ESGE) clinical guideline (2016) Endoscopy, 48, pp. 939-948; Siersema, P.D., Tan, T.G., Sutorius, F.F., Massive hemorrhage caused by a perforating Gianturco-Z stent resulting in an aortoesophageal fistula (1997) Endoscopy, 29, pp. 416-420; Allgaier, H.P., Schwacha, H., Technau, K., Fatal esophagoaortic fistula after placement of a self-expanding metal stent in a patient with esophageal carcinoma (1997) N Engl J Med, 337, p. 1778; Jager, J., Langendijk, H., Pannebakker, M., A single session of intraluminal brachytherapy in palliation of oesophageal cancer (1995) Radiother Oncol, 37, pp. 237-240; Brewster, A.E., Davidson, S.E., Makin, W.P., Intraluminal brachytherapy using the high dose rate microSelectron in the palliation of carcinoma of the oesophagus (1995) Clin Oncol (R Coll Radiol), 7, pp. 102-105; Gaspar, L.E., Nag, S., Herskovic, A., American brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Clinical research committee, American brachytherapy Society, Philadelphia, PA (1997) Int J Radiat Oncol Biol Phys, 38, pp. 127-132; Fuccio, L., Scagliarini, M., Frazzoni, L., Development of a prediction model of adverse events after stent placement for esophageal cancer (2016) Gastrointest Endosc, 83, pp. 746-752; Stahl, M., Mariette, C., Haustermans, K., Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up (2013) Ann Oncol, 24, pp. vi51-vi56; Maier, A., Pinter, H., Friehs, G.B., Self-expandable coated stent after intraluminal treatment of esophageal cancer: A risky procedure? (1999) Ann Thorac Surg, 67, pp. 781-784; Yu, Y.T., Yang, G., Liu, Y., Clinical evaluation of radiotherapy for advanced esophageal cancer after metallic stent placement (2004) World J Gastroenterol, 10, pp. 2145-2146; Welsch, J., Kup, P.G., Nieder, C., Survival and symptom relief after palliative radiotherapy for esophageal cancer (2016) J Cancer, 7, pp. 125-130; Eldeeb, H., Reza, S., Shmueli, U., External beam radiotherapy (EBRT) versus brachytherapy in the management of malignant oesophageal dysphagia: A retrospective study (2012) J BUON, 17, pp. 508-511; Suntharalingam, M., Moughan, J., Coia, L.R., 1996–1999 Patterns of Care Study. The national practice for patients receiving radiation therapy for carcinoma of the esophagus: Results of the 1996–1999 Patterns of Care Study (2003) Int J Radiat Oncol Biol Phys, 56, pp. 981-987; Fuccio, L., Guido, A., Hassan, C., Underuse of brachytherapy for the treatment of dysphagia owing to esophageal cancer. An Italian survey (2016) Dig Liver Dis, 48, pp. 1233-1236; Tagliaferri, L., Kovács, G., Aristei, C., Current state of interventional radiotherapy (brachytherapy) education in Italy: Results of the INTERACTS survey (2019) J Contemp Brachytherapy, 11, pp. 48-53; Autorino, R., Vicenzi, L., Tagliaferri, L., A National Survey of AIRO (Italian Association of Radiation Oncology) brachytherapy (Interventional Radiotherapy) study group (2018) J Contemp Brachytherapy, 10, pp. 254-259; Lettmaier, S., Strnad, V., Intraluminal brachytherapy in oesophageal cancer: Defining its role and introducing the technique (2014) J Contemp Brachytherapy, 6, pp. 236-241; Naga, S., Dallyb, M., de la Torrec, M., Recommendations for implementation of high dose rate 192Ir brachytherapy in developing countries by the Advisory Group of International Atomic Energy Agencyq (2002) Radiother Oncol, 64, pp. 297-308; Kovács, G., Tagliaferri, L., Valentini, V., Is an Interventional Oncology Center an advantage in the service of cancer patients or in the education? The Gemelli Hospital and INTERACTS experience (2017) J Contemp Brachytherapy, 9, pp. 497-498; Tagliaferri, L., Pagliara, M.M., Boldrini, L., INTERACTS (INTErventional Radiotherapy ACtive Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) procedures (2017) J Contemp Brachytherapy, 9, pp. 287-295; Morganti, A.G., Pasquarelli, L., Deodato, F., Videoconferencing to enhance the integration between clinical medicine and teaching: A feasibility study (2008) Tumori, 94, pp. 822-829; Allum, W.H., Blazeby, J.M., Griffin, S.M., Guidelines for the management of oesophageal and gastric cancer (2011) Gut, 60, pp. 1449-1472; Koeter, M., van Steenbergen, L.N., Lemmens, V.E., Hospital of diagnosis and probability to receive a curative treatment for oesophageal cancer (2014) Eur J Surg Oncol, 40, pp. 1338-1345; Tagliaferri, L., Budrukkar, A., Lenkowicz, J., ENT COBRA ONTOLOGY: The covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy) (2018) J Contemp Brachytherapy, 10, pp. 260-266; Tagliaferri, L., Gobitti, C., Colloca, G.F., A new standardized data collection system for interdisciplinary thyroid cancer management: Thyroid COBRA (2018) Eur J Intern Med, 53, p. 7378; Tagliaferri, L., Pagliara, M.M., Masciocchi, C., Nomogram for predicting radiation maculopathy in patients treated with Ruthenium-106 plaque brachytherapy for uveal melanoma (2017) J Contemp Brachytherapy, 9, pp. 540-547
PY - 2020
Y1 - 2020
N2 - Purpose: The aim of this review was to examine efficacy of palliative interventional radiotherapy (IRT) in esophageal cancer compared with other treatment in terms of dysphagia-free survival (DyFS) and safety. Methods and Material: A systematic research using PubMed, Scopus, and Cochrane library was performed to identify full articles evaluating the efficacy of IRT as palliation in patients with esophageal cancer. ClinicalTrials.gov was searched for ongoing or recently completed trials, and PROSPERO was searched for ongoing or recently completed systematic reviews. We analyzed only clinical study as full text of patients with symptomatic esophageal cancer treated with IRT alone or in combination with other treatment. Conference paper, survey, letter, editorial, book chapter, and review were excluded. Time restriction (1990–2018) as concerns the years of the publication was considered. The primary outcome was the duration of dysphagia relief (DyFS) after brachytherapy vs. other treatment (external-beam radiotherapy, photodynamic therapy, argon plasma coagulation, stent, and laser) during followup. Secondary outcomes included overall survival and adverse event rates. Results: The literature search resulted in 554 articles. Sixty-six articles were assessed via full text for eligibility. Of these, 59 articles were excluded for various reasons, leaving seven randomized studies. The number of evaluated patients was 905 patients, and median age was 70.5 years. In the IRT group, the median DyFS was 99 days, the most relevant G3–G4 toxicity were fistula development and stenosis reported, respectively, in 8.3% and 12.2%; the overall median survival was 175.5 days. Conclusion: In conclusion, we provided evidence-based support that IRT is an effective and safe treatment option; therefore, its underuse is no longer justified. © 2020 American Brachytherapy Society
AB - Purpose: The aim of this review was to examine efficacy of palliative interventional radiotherapy (IRT) in esophageal cancer compared with other treatment in terms of dysphagia-free survival (DyFS) and safety. Methods and Material: A systematic research using PubMed, Scopus, and Cochrane library was performed to identify full articles evaluating the efficacy of IRT as palliation in patients with esophageal cancer. ClinicalTrials.gov was searched for ongoing or recently completed trials, and PROSPERO was searched for ongoing or recently completed systematic reviews. We analyzed only clinical study as full text of patients with symptomatic esophageal cancer treated with IRT alone or in combination with other treatment. Conference paper, survey, letter, editorial, book chapter, and review were excluded. Time restriction (1990–2018) as concerns the years of the publication was considered. The primary outcome was the duration of dysphagia relief (DyFS) after brachytherapy vs. other treatment (external-beam radiotherapy, photodynamic therapy, argon plasma coagulation, stent, and laser) during followup. Secondary outcomes included overall survival and adverse event rates. Results: The literature search resulted in 554 articles. Sixty-six articles were assessed via full text for eligibility. Of these, 59 articles were excluded for various reasons, leaving seven randomized studies. The number of evaluated patients was 905 patients, and median age was 70.5 years. In the IRT group, the median DyFS was 99 days, the most relevant G3–G4 toxicity were fistula development and stenosis reported, respectively, in 8.3% and 12.2%; the overall median survival was 175.5 days. Conclusion: In conclusion, we provided evidence-based support that IRT is an effective and safe treatment option; therefore, its underuse is no longer justified. © 2020 American Brachytherapy Society
KW - Brachytherapy
KW - Esophageal cancer
KW - Interventional radiotherapy
KW - Palliative
KW - argon plasma coagulation
KW - brachytherapy
KW - cancer palliative therapy
KW - cancer radiotherapy
KW - cancer survival
KW - dysphagia
KW - esophagus cancer
KW - esophagus fistula
KW - esophagus stenosis
KW - external beam radiotherapy
KW - follow up
KW - human
KW - intraoperative radiotherapy
KW - outcome assessment
KW - patient safety
KW - photodynamic therapy
KW - priority journal
KW - Review
KW - systematic review
KW - adverse device effect
KW - adverse event
KW - complication
KW - esophagus tumor
KW - palliative therapy
KW - procedures
KW - radiation injury
KW - randomized controlled trial (topic)
KW - stent
KW - survival rate
KW - Deglutition Disorders
KW - Esophageal Fistula
KW - Esophageal Neoplasms
KW - Esophageal Stenosis
KW - Humans
KW - Palliative Care
KW - Radiation Injuries
KW - Randomized Controlled Trials as Topic
KW - Stents
KW - Survival Rate
U2 - 10.1016/j.brachy.2019.09.005
DO - 10.1016/j.brachy.2019.09.005
M3 - Article
VL - 19
SP - 104
EP - 110
JO - Brachytherapy
JF - Brachytherapy
SN - 1538-4721
IS - 1
ER -